Fortive Corporation Q2 FY26 Earnings Analysis

Published 29 May 2026 | Machinery | Market Cap: ₹18.0K Cr

Price

59.17

Market Cap

₹18.0K Cr

P/E Ratio

35.5

Revenue Rank

Rank 4

Margin Rank

Rank 2

Earnings Summary

- Software revenue is growing nicely ahead of the overall business, with strong early signs in innovation and commercial efforts. - Fortive delivered adjusted EPS growth of over 25% in Q1 2026, marking the third consecutive quarter of double-digit EPS growth.

📊 Revenue & Sales Performance

Rank 4

- Software revenue is growing nicely ahead of the overall business, with strong early signs in innovation and commercial efforts. - Core growth for 2026 is expected in the 2% to 3% range, trending towards the higher end of that range. - Fluke is expected to ramp up growth, potentially catching up to mid-single-digit growth levels this year, supported by new data center products and expanded connectivity offerings. - Both Intelligent Operating Solutions (iOS) and Advanced Healthcare Solutions (AHS) segments have shown accelerating growth trends, with strong demand in consumables, services, and software. - Commercial investments and accelerated innovation across segments are beginning to bear fruit, especially in North America and Europe. - Recurring revenue is growing faster than consolidated revenue in both segments, indicating improved revenue durability. - Growth in hardware-as-a-service product lines and AI-driven product innovation is supporting sustained expansion.

📈 Profitability & Margins

Rank 2

- Fortive delivered adjusted EPS growth of over 25% in Q1 2026, marking the third consecutive quarter of double-digit EPS growth. - The company reaffirms full-year 2026 adjusted EPS guidance in the range of $2.90 to $3.00, with results trending toward the upper half of this range. - Adjusted EBITDA margin expansion of 50 to 100 basis points annually is targeted, driven by productivity and growth investments. - Core revenue growth is expected to be in the 2% to 3% range for the year, with momentum pointing to the higher end of that range. - Q2 and Q3 adjusted EPS are expected to be broadly similar to Q1 levels, with some conservatism acknowledged due to early-year timing and selling days impact. - Long-term outlook remains positive, with strong confidence in executing the Fortive accelerated strategy for multi-year shareholder value creation.

🏗️ Capital Expenditure Plans

Yes

- Fortive is excited about the data center investment cycle, including construction, build-out, and ongoing operations/maintenance of massive data centers. - Fluke is actively innovating with products targeted at data center needs, e.g., the CertiFiber MAX launched in Q4 of last year, driving pull-through of complementary products. - Commercial investments are focused on high-growth verticals like data centers, defense, and distributed energy. - Advanced Healthcare Solutions (AHS) is advancing growth strategies in India, China, and EMEA with related commercial investments. - Capital allocation priorities include investing in organic growth and pursuing bolt-on M&A with a revamped team and strategic focus. - Share repurchases continue, with about $500 million deployed in Q1. - Deliberate investment in innovation and commercial initiatives underpins growth acceleration. - Overall, capital deployment balances growth initiatives, bolt-on acquisitions, share repurchases, and modest dividend growth.

💰 Fundraising & Capital Structure

No information

- No explicit mention of new fundraising through debt or equity in the current quarter or near future. - The company increased commercial paper modestly to fund share repurchases in Q1, indicating some short-term borrowing but no major new debt issuance. - Fortive maintains a strong balance sheet with 2.8x gross debt to adjusted EBITDA. - Capital allocation priorities focus on organic growth, bolt-on M&A, share repurchases, and a modest growing dividend. - No indications of plans for equity issuance; share repurchases continue actively. - The company is prepared to deploy capital for acquisitions when attractive but is focused on disciplined capital allocation with best relative returns. - Net interest expense guidance is about $135 million for the year, reflecting manageable debt levels without significant new borrowing plans.

📋 Order Book & Pipeline

Yes

- Strong order growth observed in Q1, outpacing 5.3% core revenue growth with 7.7% total revenue growth. - Order growth is broad-based across both segments: iOS, Fluke, FAW (Facility Asset Wealth), ISC, and EHS (Environmental Health & Safety). - Leading indicators such as ARR, GDR, and MDR are positive, signaling continued momentum. - The FAW business has built a strong order book over several quarters, translating into revenue growth as new orders are recognized. - Opportunistic approach on government spending for Gordian, with expectations for strong outcomes in Q2 based on current funnel and customer engagement. - No abnormal assumptions baked into Q2 guidance regarding orderbook; any upside would be incremental. - Overall, the order book reflects steady acceleration and robust demand across the portfolio.

Key Metrics

Revenue

Rank 4

Margin

Rank 2

Capex

Yes

Fundraise

No information

Order Book

Yes

Frequently Asked Questions

What were Fortive Corporation Q2 FY26 results?

- Software revenue is growing nicely ahead of the overall business, with strong early signs in innovation and commercial efforts. - Fortive delivered adjusted EPS growth of over 25% in Q1 2026, marking the third consecutive quarter of double-digit EPS growth.

What is Fortive Corporation share price analysis?

Fortive Corporation currently shows a neutral. The stock trades at a P/E of 35.5 with a market cap of $18,039. Investors should review the full earnings analysis for detailed insights.

Is Fortive Corporation planning capital expenditure?

- Fortive is excited about the data center investment cycle, including construction, build-out, and ongoing operations/maintenance of massive data centers.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.